Skip to main content

Exploiting MELanoma disease comPLEXity to address European research training needs in translational cancer systems biology and cancer systems medicine

Objective

Novel treatment options and associated personalised, patient-tailored therapies need to be explored and developed for highly heterogeneous and chemotherapy resistant cancers, such as malignant melanoma. This can only be achieved by industry-academia collaborations in newly emerging, innovative research disciplines such as translational cancer systems biology and systems medicine. These disciplines and the associated European training needs provide the foundation for the MEL-PLEX ETN. MEL-PLEX aims to understand the network-level and multi-scale regulation of disease-relevant signalling in melanoma through a combination of quantitative biomedical and computational research approaches that go significantly beyond the current state-of-the-art. Coordinated by the RCSI Centre for Systems Medicine, MEL-PLEX will train 15 early stage researchers through a highly interdisciplinary and intersectoral research training programme. MEL-PLEX comprises 11 beneficiaries and 7 partner organisations from 11 countries, including European and international leaders in personalised melanoma therapy, melanoma systems biology and cancer systems medicine. MEL-PLEX aims to (i) achieve an unmatched depth of molecular and mechanistic disease understanding, (ii) will exploit this knowledge to develop and validate predictive models for disease progression, prognosis and responsiveness to current and novel (co-)treatment options, and (iii) will provide superior and clinically relevant tools and biomarker signatures for personalising and optimising melanoma treatment. The MEL-PLEX ETN addresses current needs in academia and the private sector for researchers that have been trained in an environment that spans across biology, medicine and mathematics, that can navigate confidently between clinical, academic and private sector research environments, and that have developed an innovative and creative mindset to progress research findings towards applications.

Field of science

  • /medical and health sciences/clinical medicine/cancer/skin cancer/melanoma

Call for proposal

H2020-MSCA-ITN-2014
See other projects for this call

Funding Scheme

MSCA-ITN-ETN - European Training Networks

Coordinator

ROYAL COLLEGE OF SURGEONS IN IRELAND
Address
Saint Stephen's Green 123
2 Dublin
Ireland
Activity type
Higher or Secondary Education Establishments
EU contribution
€ 184 496,25

Participants (11)

TECHNISCHE UNIVERSITAET DRESDEN
Germany
EU contribution
€ 498 432,96
Address
Helmholtzstrasse 10
01069 Dresden
Activity type
Higher or Secondary Education Establishments
UNIVERSITE DU LUXEMBOURG
Luxembourg
EU contribution
€ 501 120
Address
2 Avenue De L'universite
4365 Esch-sur-alzette
Activity type
Higher or Secondary Education Establishments
KATHOLIEKE UNIVERSITEIT LEUVEN
Belgium
EU contribution
€ 501 120
Address
Oude Markt 13
3000 Leuven
Activity type
Higher or Secondary Education Establishments
RUPRECHT-KARLS-UNIVERSITAET HEIDELBERG

Participation ended

Germany
EU contribution
€ 55 381,44
Address
Seminarstrasse 2
69117 Heidelberg
Activity type
Higher or Secondary Education Establishments
ONCOMARK LIMITED
Ireland
EU contribution
€ 265 674,60
Address
172 Rathgar Road Rathgar
Dublin 6 Dublin
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN
Ireland
EU contribution
€ 265 674,60
Address
Belfield
4 Dublin
Activity type
Higher or Secondary Education Establishments
OPTIMATA LTD
Israel
EU contribution
€ 260 300,52
Address
20 Zichron Yaa'kov St.
6299920 Tel Aviv
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
KRAEFTENS BEKAEMPELSE
Denmark
EU contribution
€ 290 081,88
Address
Strandboulevarden 49
2100 Koebenhavn
Activity type
Research Organisations
PROTATOUANS - ETAIREIA EREYNAS VIOTECHNOLOGIAS MONOPROSOPI ETAIREIA PERIORISMENIS EYTHINIS
Greece
EU contribution
€ 242 386,92
Address
Odos Navarchou Votsi 3
16675 Glyfada
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
UNIVERSITY OF STUTTGART
Germany
EU contribution
€ 477 664,92
Address
Keplerstrasse 7
70174 Stuttgart
Activity type
Higher or Secondary Education Establishments
UNIVERSITAETSKLINIKUM AACHEN

Participation ended

Germany
EU contribution
€ 41 536,08
Address
Pauwelsstrasse 30
52074 Aachen
Activity type
Higher or Secondary Education Establishments

Partners (8)

University Berne
Switzerland
Address

Berne
Activity type
Other
Merrimack
United States
Address

North Andover
Activity type
Other
Apogenix
Germany
Address
Im Neuenheimer Feld 584
69120 Heidelberg
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Novartis
Germany
Address
Roonstrasse 25
90429 Nurnberg
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
A. Plaisant Srl.
Italy
Address

Roma
Activity type
Other
Mass. General Hospital
United States
Address

Boston
Activity type
Other
Galderma
France
Address

Chede
Activity type
Other
THE HEBREW UNIVERSITY OF JERUSALEM
Israel
Address
Edmond J Safra Campus Givat Ram
91904 Jerusalem
Activity type
Higher or Secondary Education Establishments